Evidence map›Paper›PMID 40974477›Full record

ArticleAbdominal radiology (New York)2026

Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer.

Alexander Herold, Maximilian Pohl, Stephan M Korn, Michael Weber, Jason A Efstathiou, Philip J Saylor, Susie Y Huang, Mukesh G Harisinghani, Onofrio A Catalano

Abstract read
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander HeroldDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Maximilian PohlDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Stephan M KornDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Michael WeberDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Philip J SaylorMassachusetts General Hospital Cancer Center, Boston, USA.
Susie Y HuangDepartment of Radiology, Martinos Center for Biomedical Imaging, Harvard Medical School, Boston, USA.
Mukesh G HarisinghaniDivision of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Onofrio A CatalanoDivision of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. onofriocatalano@yahoo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate whether pretreatment multiparametric MRI features can predict biochemical recurrence in patients with localized prostate cancer treated with radiation therapy of curative intent.

methodsThis retrospective single-institution study analyzed patients with prostate cancer who underwent primary radiotherapy between January 2015 and December 2019. All patients underwent pretreatment multiparametric MRI, with or without endorectal coil. Clinical, pathological and MRI features were assessed, with emphasis on qualitative and quantitative imaging characteristics. Univariate binary logistic regression identified significant predictors of recurrence. Variables showing significance (p < 0.05) were included in forward stepwise logistic regression analysis. The primary endpoint was biochemical recurrence, defined by Phoenix criteria.

resultsThe study included 54 patients (mean age 76.57 ± 7.77 years), with 10 patients (18.5%) experiencing biochemical recurrence at a median follow-up of 74.4 months. In univariate analysis, clinical T-stage (OR: 2.24, 95% CI: 1.11-4.56), ISUP grade (OR: 1.86, 95% CI: 1.03-3.37) and NCCN risk groups (OR: 2.55, 95% CI: 1.16-5.62) were significant predictors. Among MRI parameters, total tumor volume (OR: 4.28, 95% CI: 1.59-11.57), extraprostatic extension (OR: 8.57, 95% CI: 1.61-45.73), neurovascular bundle invasion (NBI) (OR: 14.78, 95% CI: 2.97-73.44), and seminal vesicle invasion (OR: 15.00, 95% CI: 2.94-76.56) showed strong associations with recurrence. In stepwise multivariate analysis, NBI emerged as the sole independent predictor (OR: 3.16, 95% CI: 1.59-6.28, p = 0.001), with 86.4% specificity and 92.7% negative predictive value.

conclusionNBI on pretreatment MRI independently predicts biochemical recurrence in patients with localized prostate cancer treated with radiation therapy, highlighting the need to refine risk stratification by incorporating imaging criteria.

Indexed as

Magnetic Resonance ImagingMultiparametric Magnetic Resonance ImagingNeoplasm Recurrence, LocalProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedPredictive Value of TestsPrognosisProstate-Specific AntigenRetrospective StudiesProstate-Specific AntigenBiochemical recurrenceMagnetic resonance imagingProstate cancerRadiation therapyRisk stratification

Identifiers

PMID40974477

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.